SOUTH SAN FRANCISCO, Calif. (AP) _ CytomX Therapeutics Inc. (CTMX) on Tuesday reported a loss of $23.4 million in its third quarter.
On a per-share basis, the South San Francisco, California-based company said it had a loss of 53 cents.
The results did not meet Wall Street expectations. The average estimate of seven analysts surveyed by Zacks Investment Research was for a loss of 42 cents per share.
The biopharmaceutical company posted revenue of $12.5 million in the period, which also fell short of Street forecasts. Five analysts surveyed by Zacks expected $16.4 million.
CytomX Therapeutics shares have declined 40 percent since the beginning of the year. In the final minutes of trading on Tuesday, shares hit $12.75, a decrease of 36 percent in the last 12 months.
This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on CTMX at https://www.zacks.com/ap/CTMX